On August 19, a new association of pharmaceutical research teams was launched under the name CARE (Corona Accelerated R&D in Europe) and backed by the IMI (Innovative Medicines Initiative) to move the research for Covid-19 further forward and develop treatment solutions in time.
The initiative is funded by the European Union, eleven members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and three partners from the IMI. The total funds collected amounted to 77.7 million euros.
The CARE project is a five-year long collaboration among 37 associates from the United States, United Kingdom, Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, and Switzerland. It is spearheaded by the French National Institute of Health and Medical Research, Janssen Pharmaceutica, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Takeda Pharmaceuticals International. All projects intended for Covid-19 beginning February will be joined as one.
Scientific research firms all over the world are now joining forces to combat the global threat that we are currently facing. The expertise of all 37 partners will now be utilized to coordinate a strategic plan of treatment development for Covid-19. After laboratory research and testing, drug candidates will immediately forward to clinical trials on human subjects. Drug repurposing will also be done together with the Rega Institute for Medical Research.
CARE is stood upon three main targets:
- Drug repositioning/repurposing
Existing drug compounds will be reviewed for other possible indications.
Studying the molecular structure of a compound and figure out ways to chemically modify them and produce another compound with a different pharmacological action.
Using human and yeast culture, immunity testing on mammals, and patient beta cells.
“CARE aims to create effective therapies with a positive safety profile for the COVID-19 pandemic (drug repositioning), and develop new drugs and antibodies specially designed to tackle the SARS-CoV-2 virus.”
There aren’t any approved vaccines so far and only a few medications available for use against the disease. The distribution of the available drugs is not enough to cater to the still-rising number of cases in several countries. This initiative is a step in the right direction to the permanent solution for the plague that haunts mankind today.